News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Protein Design Labs, Inc. (PDLI) Announces Webcast Of R&D Update At 8 AM EDT On October 7


10/19/2005 5:13:17 PM

FREMONT, Calif., Oct. 3 /PRNewswire-FirstCall/ -- Protein Design Labs, Inc. (PDL) today announced that it will conduct a live webcast of its R&D Update presentation to the financial community. The live webcast will begin at 8:00 a.m. Eastern Daylight Time on October 7, and is expected to conclude by 11:00 a.m. Eastern Daylight Time.

Steven Benner, M.D., Senior Vice President and Chief Medical Officer, PDL, will host the R&D Update and webcast. Joining him from the company will be Richard Murray, Ph.D., Senior Vice President, Chief Scientific and Technical Officer.

In addition, presentations by leading physicians in the areas of liver disease, ulcerative colitis and heart failure will be made as follows:

Samuel Sigal, M.D., Center for Liver Disease and Transplantation, Weill Cornell Medical Center, New York, will discuss research on terlipressin for the treatment of type I hepatorenal syndrome.

Lloyd F. Mayer, M.D., Professor and Director of the Center for Immunobiology at The Mount Sinai Hospital, New York, will discuss current research on Nuvion(R) (visilizumab) for the treatment of intravenous steroid- refractory ulcerative colitis.

Markus Meyer, M.D., co-founder and Managing Director of Cardiopep Pharma GmbH, Hannover, Germany will review the development and early research on ularitide for the treatment of acute decompensated heart failure.

Veselin Mitrovic, M.D., Medical Director of the Research Unit / Kerckhoff Clinic, Bad Nauheim, Germany, will present the recently announced SIRIUS II data on ularitide for the treatment of acute decompensated heart failure.

Dr. Benner will update the clinical development plans and timelines for PDL's products in development, including visilizumab, ularitide, daclizumab, volociximab and HuZAF(TM) (fontolizumab). Dr. Murray will present a summary of PDL's ongoing antibody discovery and research efforts.

The live webcast will be available through the PDL website: www.pdl.com. Please connect to this website at least 15 minutes prior to the live webcast to allow time for any software download that may be needed to hear the webcast. A replay, including the presentation materials, will be available at www.pdl.com starting approximately one hour after completion of the webcast.

PDL's Second Annual R&D Update will take place at the Four Seasons Hotel, Cosmopolitan Room, 57 East 57th Street, New York, NY 10022. Additional information on attending the Update can be obtained by contacting Jade Cantor at (212) 843-0211 or jcantor@lazarpartners.com

About Protein Design Labs

PDL is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a leader in the development of humanized antibodies, PDL has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products. Further information on PDL is available at www.pdl.com.

Protein Design Labs, the PDL logo and Nuvion are registered U.S. trademarks and HuZAF is a trademark of Protein Design Labs, Inc.

Protein Design Labs, Inc.

CONTACT: James R. Goff, Sr. Director, Investor Relations, of ProteinDesign Labs, Inc., +1-510-574-1421 or jgoff@pdl.com, or Jade Cantor ofLazar Partners, +1-212-843-0211 or jcantor@lazarpartners.com, for ProteinDesign Labs, Inc.


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES